As per 30 September 2026, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,636,514 shares. All shares are common shares. The total number of votes is 357,636,514. The increase in the number of shares and votes results from the issue of 223,677 class C shares. The class C shares were issued for the purpose of ensuring fulfilment of commitments under the long-term incentive programme for permanent employees (the All Employee Programme) and have by virtue of the conversion clause in the articles of association been converted to common shares. As per 30 September 2026 the company holds 9,631,955 common shares.
Sobi®
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
Gerard Tobin
Head of Investor Relations
This information is information that Sobi is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication on 30 September 2026 at 08.00 CEST.